Management ChangeAug 10, 2026, 08:51 AM
Fulcrum Therapeutics Appoints Alan Musso as Principal Accounting Officer
AI Summary
Fulcrum Therapeutics announced that Greg Tourangeau's tenure as Vice President, Finance and principal accounting officer concluded on August 7, 2026, as previously agreed. Following his departure, the Board of Directors appointed Alan Musso, the company's chief financial officer and principal financial officer, to also serve as principal accounting officer, effective August 7, 2026. Mr. Musso will not receive additional compensation for this new role.
Key Highlights
- Greg Tourangeau's tenure as Vice President, Finance and principal accounting officer ended on August 7, 2026.
- Alan Musso, Fulcrum's chief financial officer, was appointed as principal accounting officer.
- Mr. Musso's appointment as principal accounting officer is effective August 7, 2026.
- Mr. Musso will not receive any additional compensation for this new appointment.
- The change follows a previously disclosed mutual agreement for Mr. Tourangeau's departure.
Price Impact
More from FULC